Senior Refractory Specialist Jobs | Glassdoor

Senior Refractory Specialist Jobs

17 Jobs
Created with Sketch.
Filters
Created with Sketch.
Filters
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    21 days ago 21d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/Q4… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • Atara Biotherapeutics – South San Francisco, CA
    Est. Salary $66k-$180k
    13 days ago 13d
    approval in two separate indications, the treatment of rituximab-refractory EBV-PTLD after HCT and after SOT. In February 2015, the FDA… therapy designation for ATA129 in the treatment of rituximab-refractory EBV-PTLD after HCT. Breakthrough therapy designation is an…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    12 days ago 12d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    13 days ago 13d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    13 days ago 13d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    13 days ago 13d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
  • 4.2
    Agios Pharmaceuticals – Cambridge, MA
    13 days ago 13d
    medication, Enasidenib, studied for the treatment of Relapse Refractory AML with an IDH2 mutation. With launch anticipated in Q3/… subsequent approvals, additional front-line leaders and sales specialists will be hired, the geography will reduce in size, and the…
Page 1 of 1
Be the first to get new jobs like these: